Novartis drug Femara® is superior to tamoxifen after breast cancer surgery
- Details
- Category: Novartis
![Novartis Novartis](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
Nycomed reports sustained momentum in second quarter 2009
- Details
- Category: Nycomed
![Nycomed Nycomed](http://www.worldpharmanews.com/images/stories/logo/nycomed.gif)
Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research
- Details
- Category: Pfizer
![Pfizer Inc. Pfizer Inc.](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis
- Details
- Category: Novartis
![Novartis Novartis](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)
- Details
- Category: Product
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that Soliris(R) (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS).
Positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab)
- Details
- Category: Amgen
![Amgen Amgen](http://www.worldpharmanews.com/images/stories/logo/amgen.gif)
Pandemic (H1N1) 2009 influenza update
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline (GSK) GlaxoSmithKline (GSK)](http://www.worldpharmanews.com/images/stories/logo/gsk.gif)
More Pharma News ...
- Sanofi Pasteur submits supplemental application for A(H1N1) pandemic vaccine to U.S. FDA
- Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Next Generation Anti-Infective
- Studies Highlight Potential New Option in the Treatment of Bone Loss
- Sandoz launches first generic version of Prograf® capsules
- Abbott Partners With Beech-Nut to Provide New Parents with Nutrition Education and Support
- Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD
- Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 (Tovok)